Loading
Loading
Research Overview
GLP-1 and glucagon dual receptor agonist similar to survodutide; activates energy expenditure through glucagon receptor-mediated thermogenesis while reducing caloric intake via central GLP-1 signalling.
Mazdutide (IBI362) is a synthetic peptide designed to act as a dual agonist at GLP-1 and glucagon receptors. Laboratory investigations have examined its activity profile across in vitro receptor binding assays and animal model systems, focusing on hepatic lipid biology and metabolic regulation.
In preclinical research, mazdutide has been studied for its effects on hepatic triglyceride content and circulating lipid fractions. Animal model studies have examined whether the glucagon receptor component contributes to increased lipolysis and altered fatty acid oxidation in liver tissue.
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, mazdutide (glp-1/glucagon dual agonist) has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Mazdutide (GLP-1/Glucagon Dual Agonist) research is most relevant to protocols examining:
GLP-1/glucagon dual agonism research in Asian metabolic populations
NASH research and hepatic lipid metabolism studies
Researchers tracking emerging Chinese pipeline obesity compounds
Comparative mechanism studies with Survodutide
Initial phase
Compound begins accumulating in target tissue. Most researchers note subtle changes by end of week one. Baseline measurements recommended.
Early response
Measurable effects begin to establish. Mid-cycle assessment is appropriate at this point in well-designed protocols.
Peak activity window
Effects compound in this window. Given limited human data, careful documentation is important.
Washout & review
Allow full washout (~5× half-life: ~7 days). Review data, confirm baseline recovery before any repeat protocol.
GLP-1 and glucagon dual receptor agonist similar to survodutide; activates energy expenditure through glucagon receptor-mediated thermogenesis while reducing caloric intake via central GLP-1 signalling.
| Parameter | Value |
|---|---|
| Dose range | Under investigation |
| Schedule | Once weekly |
| Route | Subcutaneous |
| Half-life | ~7 days |
Available from Capital Peptides
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.